Second-quarter report 2020
Q2, April - June · Net sales amounted to MSEK 688.9 (387.4). This corresponds to an increase of 78% for the period. The organic growth during the second quarter was -10%, currency impact 0% and 88% relates to the acquisition of Trimb in 2019 and the acquired product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson (see below). · EBIT (Operating Profit) amounted to MSEK 98.6 (20.3) corresponding to a 385% growth. · Adjusted EBITDA* amounted to MSEK 213.7 (137.8) corresponding to a 55% growth. This excluding non-recurring items related to a new valuation method